October 6, 2021 AlzeCure Pharma develops novel analgesic drug based on Nobel prize-winning discoveries
October 5, 2021 New data showing the potential of the NeuroRestore project in depression presented at ECNP 2021 conference
October 4, 2021 AlzeCure’s Alzheimer project has initiated the next clinical phase I study with ACD856
August 30, 2021 AlzeCure’s Alzheimer’s project receives approval to start next clinical phase I study with ACD856
August 27, 2021 AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses
August 17, 2021 AlzeCure gives live streamed strategy update on Alzheimer’s disease and NeuroRestore on September 1
August 12, 2021 AlzeCure to present abstract at ECNP conference on NeuroRestore project’s potential in depression
July 29, 2021 New data supporting targeting Trk receptors with ACD856 for treatment of Alzheimer’s disease presented at AAIC 2021
June 11, 2021 New results from AlzeCure’s pain project TrkA-NAM presented at the IASP pain conference
June 10, 2021 Positive clinical data on the novel non-opioid VR1 antagonist ACD440 presented at IASP pain conference
April 27, 2021 AlzeCure gets late-breaking abstract on ACD440 in neuropathic pain accepted for presentation
